Overview

An Efficacy and Safety Study of Elagolix (NBI-56418) in Women With Endometriosis

Status:
Completed
Trial end date:
2009-08-28
Target enrollment:
Participant gender:
Summary
This study is designed to see how elagolix works compared to placebo in women with endometriosis and to see the effect, if any, on bone mineral density.
Phase:
Phase 2
Details
Lead Sponsor:
AbbVie
AbbVie (prior sponsor, Abbott)